Late gastrointestinal toxicities following radiation therapy for prostate cancer

Sung Kim, Shunhua Shen, Dirk F. Moore, Weichung Shih, Yong Lin, Hui Li, Matthew Dolan, Yu Hsuan Shao, Grace L. Lu-Yao

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Radiation therapy is commonly used to treat localized prostate cancer; however, representative data regarding treatment-related toxicities compared with conservative management are sparse. Objective: To evaluate gastrointestinal (GI) toxicities in men treated with either primary radiation or conservative management for T1-T2 prostate cancer. Design, setting, and participants: We performed a population-based cohort study, using Medicare claims data linked to the Surveillance Epidemiology and End Results data. Competing risk models were used to evaluate the risks. Measurements: GI toxicities requiring interventional procedures occurring at least 6 mo after cancer diagnosis. Results and limitations: Among 41 737 patients in this study, 28 088 patients received radiation therapy. The most common GI toxicity was GI bleeding or ulceration. GI toxicity rates were 9.3 per 1000 person-years after three-dimensional conformal radiotherapy, 8.9 per 1000 person-years after intensity-modulated radiotherapy, 5.3 per 1000 person-years after brachytherapy alone, 20.1 per 1000 person-years after proton therapy, and 2.1 per 1000 person-years for conservative management patients. Radiation therapy is the most significant factor associated with an increased risk of GI toxicities (hazard ratio [HR]: 4.74; 95% confidence interval [CI], 3.97-5.66). Even after 5 yr, the radiation group continued to experience significantly higher rates of new GI toxicities than the conservative management group (HR: 3.01; 95% CI, 2.06-4.39). Because our cohort of patients were between 66 and 85 yr of age, these results may not be applicable to younger patients. Conclusions: Patients treated with radiation therapy are more likely to have procedural interventions for GI toxicities than patients with conservative management, and the elevated risk persists beyond 5 yr.

Original languageEnglish
Pages (from-to)908-916
Number of pages9
JournalEuropean Urology
Volume60
Issue number5
DOIs
Publication statusPublished - Nov 2011
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Confidence Intervals
Proton Therapy
Radiation
Background Radiation
Conformal Radiotherapy
Intensity-Modulated Radiotherapy
Brachytherapy
Medicare
Epidemiology
Cohort Studies
Conservative Treatment
Hemorrhage
Population
Neoplasms

Keywords

  • Late gastrointestinal toxicity
  • Medicare
  • Prostate cancer
  • Radiation therapy
  • Surveillance Epidemiology and End Results program

ASJC Scopus subject areas

  • Urology

Cite this

Kim, S., Shen, S., Moore, D. F., Shih, W., Lin, Y., Li, H., ... Lu-Yao, G. L. (2011). Late gastrointestinal toxicities following radiation therapy for prostate cancer. European Urology, 60(5), 908-916. https://doi.org/10.1016/j.eururo.2011.05.052

Late gastrointestinal toxicities following radiation therapy for prostate cancer. / Kim, Sung; Shen, Shunhua; Moore, Dirk F.; Shih, Weichung; Lin, Yong; Li, Hui; Dolan, Matthew; Shao, Yu Hsuan; Lu-Yao, Grace L.

In: European Urology, Vol. 60, No. 5, 11.2011, p. 908-916.

Research output: Contribution to journalArticle

Kim, S, Shen, S, Moore, DF, Shih, W, Lin, Y, Li, H, Dolan, M, Shao, YH & Lu-Yao, GL 2011, 'Late gastrointestinal toxicities following radiation therapy for prostate cancer', European Urology, vol. 60, no. 5, pp. 908-916. https://doi.org/10.1016/j.eururo.2011.05.052
Kim, Sung ; Shen, Shunhua ; Moore, Dirk F. ; Shih, Weichung ; Lin, Yong ; Li, Hui ; Dolan, Matthew ; Shao, Yu Hsuan ; Lu-Yao, Grace L. / Late gastrointestinal toxicities following radiation therapy for prostate cancer. In: European Urology. 2011 ; Vol. 60, No. 5. pp. 908-916.
@article{889b1ab9b39e4913a2f529180ba7654f,
title = "Late gastrointestinal toxicities following radiation therapy for prostate cancer",
abstract = "Background: Radiation therapy is commonly used to treat localized prostate cancer; however, representative data regarding treatment-related toxicities compared with conservative management are sparse. Objective: To evaluate gastrointestinal (GI) toxicities in men treated with either primary radiation or conservative management for T1-T2 prostate cancer. Design, setting, and participants: We performed a population-based cohort study, using Medicare claims data linked to the Surveillance Epidemiology and End Results data. Competing risk models were used to evaluate the risks. Measurements: GI toxicities requiring interventional procedures occurring at least 6 mo after cancer diagnosis. Results and limitations: Among 41 737 patients in this study, 28 088 patients received radiation therapy. The most common GI toxicity was GI bleeding or ulceration. GI toxicity rates were 9.3 per 1000 person-years after three-dimensional conformal radiotherapy, 8.9 per 1000 person-years after intensity-modulated radiotherapy, 5.3 per 1000 person-years after brachytherapy alone, 20.1 per 1000 person-years after proton therapy, and 2.1 per 1000 person-years for conservative management patients. Radiation therapy is the most significant factor associated with an increased risk of GI toxicities (hazard ratio [HR]: 4.74; 95{\%} confidence interval [CI], 3.97-5.66). Even after 5 yr, the radiation group continued to experience significantly higher rates of new GI toxicities than the conservative management group (HR: 3.01; 95{\%} CI, 2.06-4.39). Because our cohort of patients were between 66 and 85 yr of age, these results may not be applicable to younger patients. Conclusions: Patients treated with radiation therapy are more likely to have procedural interventions for GI toxicities than patients with conservative management, and the elevated risk persists beyond 5 yr.",
keywords = "Late gastrointestinal toxicity, Medicare, Prostate cancer, Radiation therapy, Surveillance Epidemiology and End Results program",
author = "Sung Kim and Shunhua Shen and Moore, {Dirk F.} and Weichung Shih and Yong Lin and Hui Li and Matthew Dolan and Shao, {Yu Hsuan} and Lu-Yao, {Grace L.}",
year = "2011",
month = "11",
doi = "10.1016/j.eururo.2011.05.052",
language = "English",
volume = "60",
pages = "908--916",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Late gastrointestinal toxicities following radiation therapy for prostate cancer

AU - Kim, Sung

AU - Shen, Shunhua

AU - Moore, Dirk F.

AU - Shih, Weichung

AU - Lin, Yong

AU - Li, Hui

AU - Dolan, Matthew

AU - Shao, Yu Hsuan

AU - Lu-Yao, Grace L.

PY - 2011/11

Y1 - 2011/11

N2 - Background: Radiation therapy is commonly used to treat localized prostate cancer; however, representative data regarding treatment-related toxicities compared with conservative management are sparse. Objective: To evaluate gastrointestinal (GI) toxicities in men treated with either primary radiation or conservative management for T1-T2 prostate cancer. Design, setting, and participants: We performed a population-based cohort study, using Medicare claims data linked to the Surveillance Epidemiology and End Results data. Competing risk models were used to evaluate the risks. Measurements: GI toxicities requiring interventional procedures occurring at least 6 mo after cancer diagnosis. Results and limitations: Among 41 737 patients in this study, 28 088 patients received radiation therapy. The most common GI toxicity was GI bleeding or ulceration. GI toxicity rates were 9.3 per 1000 person-years after three-dimensional conformal radiotherapy, 8.9 per 1000 person-years after intensity-modulated radiotherapy, 5.3 per 1000 person-years after brachytherapy alone, 20.1 per 1000 person-years after proton therapy, and 2.1 per 1000 person-years for conservative management patients. Radiation therapy is the most significant factor associated with an increased risk of GI toxicities (hazard ratio [HR]: 4.74; 95% confidence interval [CI], 3.97-5.66). Even after 5 yr, the radiation group continued to experience significantly higher rates of new GI toxicities than the conservative management group (HR: 3.01; 95% CI, 2.06-4.39). Because our cohort of patients were between 66 and 85 yr of age, these results may not be applicable to younger patients. Conclusions: Patients treated with radiation therapy are more likely to have procedural interventions for GI toxicities than patients with conservative management, and the elevated risk persists beyond 5 yr.

AB - Background: Radiation therapy is commonly used to treat localized prostate cancer; however, representative data regarding treatment-related toxicities compared with conservative management are sparse. Objective: To evaluate gastrointestinal (GI) toxicities in men treated with either primary radiation or conservative management for T1-T2 prostate cancer. Design, setting, and participants: We performed a population-based cohort study, using Medicare claims data linked to the Surveillance Epidemiology and End Results data. Competing risk models were used to evaluate the risks. Measurements: GI toxicities requiring interventional procedures occurring at least 6 mo after cancer diagnosis. Results and limitations: Among 41 737 patients in this study, 28 088 patients received radiation therapy. The most common GI toxicity was GI bleeding or ulceration. GI toxicity rates were 9.3 per 1000 person-years after three-dimensional conformal radiotherapy, 8.9 per 1000 person-years after intensity-modulated radiotherapy, 5.3 per 1000 person-years after brachytherapy alone, 20.1 per 1000 person-years after proton therapy, and 2.1 per 1000 person-years for conservative management patients. Radiation therapy is the most significant factor associated with an increased risk of GI toxicities (hazard ratio [HR]: 4.74; 95% confidence interval [CI], 3.97-5.66). Even after 5 yr, the radiation group continued to experience significantly higher rates of new GI toxicities than the conservative management group (HR: 3.01; 95% CI, 2.06-4.39). Because our cohort of patients were between 66 and 85 yr of age, these results may not be applicable to younger patients. Conclusions: Patients treated with radiation therapy are more likely to have procedural interventions for GI toxicities than patients with conservative management, and the elevated risk persists beyond 5 yr.

KW - Late gastrointestinal toxicity

KW - Medicare

KW - Prostate cancer

KW - Radiation therapy

KW - Surveillance Epidemiology and End Results program

UR - http://www.scopus.com/inward/record.url?scp=80053311342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053311342&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2011.05.052

DO - 10.1016/j.eururo.2011.05.052

M3 - Article

VL - 60

SP - 908

EP - 916

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -